ecallantide + placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bloodloss
Conditions
Bloodloss, Surgical Procedures, Operative
Trial Timeline
Mar 1, 2009 → Jan 1, 2010
NCT ID
NCT00816023About ecallantide + placebo
ecallantide + placebo is a phase 2 stage product being developed by Merck for Bloodloss. The current trial status is completed. This product is registered under clinical trial identifier NCT00816023. Target conditions include Bloodloss, Surgical Procedures, Operative.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00816023 | Phase 2 | Completed |
| NCT00448864 | Phase 2 | Terminated |
Competing Products
1 competing product in Bloodloss
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ecallantide + Cyklokapron(R) | Merck | Phase 2 | 52 |